In summary, our findings show that NCOA2 is frequently amplified in breast cancer and loss of NCOA2 remarkably attenuates cell growth in breast cancer cell lines with different NR status, strongly indicating that NCOA2 might be a potential target for breast cancer treatment. Here, NCOA2 is linked to breast carcinoma.